Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Tempus AI, Inc. Class A ( (TEM) ).
On August 8, 2025, Tempus AI, Inc. reported significant financial growth for the second quarter of 2025, with a revenue increase of 89.6% year-over-year, reaching $314.6 million. The company saw substantial growth in genomics and data services, contributing to a gross profit increase of 158.3%. Tempus also issued $750 million in convertible senior notes to enhance financial flexibility. The company is expanding its AI-powered clinical tools and has reached a milestone of over 40 million clinical patient records, reflecting its leadership in AI and oncology as it approaches its 10th anniversary.
The most recent analyst rating on (TEM) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Tempus AI, Inc. Class A stock, see the TEM Stock Forecast page.
Spark’s Take on TEM Stock
According to Spark, TipRanks’ AI Analyst, TEM is a Neutral.
Tempus AI, Inc. scores moderately low due to significant profitability and financial stability concerns, despite strong revenue growth and positive future guidance. Technical indicators and valuation metrics present challenges, while the partnership with AstraZeneca offers a positive outlook.
To see Spark’s full report on TEM stock, click here.
More about Tempus AI, Inc. Class A
Tempus AI, Inc. is a technology company specializing in the application of artificial intelligence to advance precision medicine and patient care. The company provides AI-enabled precision medicine solutions to physicians, aiming to deliver personalized patient care and facilitate the discovery, development, and delivery of optimal therapeutics.
Average Trading Volume: 11,765,539
Technical Sentiment Signal: Buy
Current Market Cap: $9.61B
For a thorough assessment of TEM stock, go to TipRanks’ Stock Analysis page.